Compare AU
Compare NDQ vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Nasdaq 100 ETF (NDQ) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
NDQ | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 5,847 | 80 |
Median incremental investment | $997.50 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,962.06 | $1,284.19 |
Average age group | 26 - 35 | > 35 |
Key Summary
NDQ | CURE | |
|---|---|---|
Strategy | BetaShares Nasdaq 100 ETF (ASX: NDQ) seeks to track the performance of the NASDAQ 100 index before account fees, expenses and taxes. The index tracks 100 of the largest non-financial companies listed on the NASDAQ market. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | APPLE INC (8.87 %) NVIDIA CORP (8.41 %) MICROSOFT CORP (8.12 %) | Neurocrine Biosciences Inc (2.72 %) Natera Inc (2.49 %) Gilead Sciences Inc (2.45 %) |
Top 3 industries | Information Technology (50.23 %) Consumer Discretionary (14.75 %) Communication Services (11.95 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.15 %) Netherlands (0.92 %) Brazil (0.69 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.48 % | 0.45 % |
Key Summary
NDQ | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | NASDAQ 100 Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.48 % | 0.45 % |
Price | $51.07 | $48.46 |
Size | $6.069 billion | $34.226 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.88 % | 4.24 % |
Market | ASX | ASX |
First listed date | 26/05/2015 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
NDQ | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 5,847 | 80 |
Median incremental investment | $997.50 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,962.06 | $1,284.19 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
NDQ | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
NDQ | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |